Dosing underway in AIM ImmunoTech Ampligen in combo trial in COVID-19 with cancer

 

• The first patient have been dosed and treated in AIM ImmunoTech (NYSEMKT:AIM) Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19.
• Funding for the clinical trial is provided through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.
• Additionally, the AIM team is working to develop; an intranasal prophylaxis strategy for frontline workers, the elderly and other high-risk patients, including those with co-morbidities such as cancer and an effective therapy for COVID-19 Long Haulers, so named due to the persistence of their symptoms after their infections have ended.
• Previously in Sep.16, AIM ImmunoTech/Roswell Park initiates enrollment in combo trial in COVID-19 patients with cancer
• https://seekingalpha.com/news/3639344-dosing-underway-in-aim-immunotechs-ampligen-in-combo-trial-in-covidminus-19-patients-cancer